Acquisitive Canadian pharmaceuticals company Valeant is on the verge of finalising an agreement to buy US gastrointestinal drug specialist Salix for more than $9.7bn, sources told the Financial Times.
PressDigest
Valeant closes in on $9.7bn-plus takeover of Salix
Acquisitive Canadian pharmaceuticals company Valeant is on the verge of finalising an agreement to buy US gastrointestinal drug specialist Salix for more than $9.7bn, sources told the Financial Times.